In short
The EPOPEX clinical trial is an open-label extension study designed to evaluate the long-term clinical benefits and safety of DBV712, also known as Viaskin Peanut, in children with peanut allergies. This study aims to assess the effectiveness of epicutaneous immunotherapy (EPIT) in inducing and maintaining desensitization to peanuts over a period of up to 3 years. The trial focuses on children who have completed the previous EPITOPE study and will provide valuable insights into the sustained effects of this innovative treatment approach for peanut allergies.
At a glance
- Study Type
- Phase III, single-arm, open-label, uncontrolled study
- Treatment
- Viaskin Peanut patch (250 μg peanut protein)
- Duration
- Up to 3 years
- Primary Objectives
- Assess clinical benefit and safety of long-term Viaskin Peanut treatment
- Key Endpoints
- Proportion of subjects tolerating ≥1000 mg peanut protein, treatment responders, cumulative reactive dose, adverse events
- Eligibility
- Children who completed the EPITOPE study with documented DBPCFC at Month 12
- Safety Monitoring
- Adverse events, local skin reactions, laboratory data, physical examinations, vital signs, spirometry results
- Additional Assessments
- Peanut-specific antibodies, skin prick tests, quality of life questionnaires, epigenetic modifications
What is ARACHIS HYPOGAEA FLOUR?
ARACHIS HYPOGAEA FLOUR, also known as peanut flour, is a substance derived from peanuts. In the context of medical research, it is being studied as a potential treatment for peanut allergies in children. This flour contains peanut proteins, which are the components that typically trigger allergic reactions in people with peanut allergies.
How is it used in peanut allergy treatment?
Researchers are exploring the use of ARACHIS HYPOGAEA FLOUR in a treatment approach called epicutaneous immunotherapy (EPIT). This method involves exposing the patient to small amounts of peanut protein through the skin, with the goal of gradually desensitizing the immune system to peanuts.
The EPOPEX Study
The EPOPEX (EPITOPE Open-label Extension) study is a clinical trial designed to evaluate the long-term benefits and safety of a treatment called DBV712 (also known as Viaskin Peanut) for children with peanut allergies. This study follows up on a previous trial called EPITOPE, which tested the initial effectiveness of the treatment.
Who can participate in the study?
The study is primarily aimed at children who completed the previous EPITOPE study. Participants must have:
- Completed the EPITOPE study, including a final food challenge test
- Parents or guardians willing to provide informed consent
- The ability to comply with all study requirements
However, children with certain conditions may not be eligible, including those with:
- Severe anaphylactic reactions during the previous study
- Uncontrolled asthma or other serious medical conditions
- Certain skin conditions that might interfere with the treatment
What does the treatment involve?
The treatment in the EPOPEX study involves:
- Application of a patch containing peanut protein (Viaskin Peanut) to the skin
- Regular check-ups and tests to monitor progress and safety
- Food challenges, where participants consume small amounts of peanut protein under medical supervision to assess their tolerance
The study uses different formulations of peanut protein, including:
- A low-dose oral paste (6.6 mg/g peanut proteins)
- A high-dose oral paste (133.3 mg/g peanut proteins)
- A placebo (for comparison in some parts of the study)
Potential Benefits
The researchers hope to see several potential benefits from this treatment, including:
- Increased tolerance to peanuts, potentially allowing children to safely consume larger amounts
- Reduced risk of severe allergic reactions from accidental peanut exposure
- Improved quality of life for children with peanut allergies and their families
Safety Considerations
As with any medical treatment, there are potential risks and side effects. The study closely monitors participants for:
- Allergic reactions, including anaphylaxis
- Skin reactions at the patch application site
- Any other adverse events that may occur during the study
Participants will have access to emergency medications and medical care throughout the study.
Conclusion
The EPOPEX study represents an important step in researching potential treatments for peanut allergies in children. By using ARACHIS HYPOGAEA FLOUR (peanut flour) in a controlled manner, researchers hope to develop a safe and effective way to reduce the impact of peanut allergies. However, it's important to remember that this is still a research study, and the treatment is not yet approved for general use. Parents of children with peanut allergies should continue to follow their doctor's advice for managing the allergy.